Antares Pharma, Inc. (NASDAQ:ATRS) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued on Monday, October 16th.
ATRS has been the topic of a number of other research reports. Piper Jaffray Companies restated a “buy” rating on shares of Antares Pharma in a research report on Friday, September 8th. HC Wainwright set a $5.00 price target on shares of Antares Pharma and gave the stock a “buy” rating in a research report on Friday, October 13th. Vetr upgraded shares of Antares Pharma from a “hold” rating to a “buy” rating and set a $3.30 price target on the stock in a research report on Wednesday, July 5th. Finally, Chardan Capital started coverage on shares of Antares Pharma in a research report on Friday, June 23rd. They issued a “buy” rating and a $5.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $3.84.
Shares of Antares Pharma (ATRS) traded up 3.23% during midday trading on Monday, reaching $1.92. 1,537,760 shares of the company’s stock traded hands. The stock’s market cap is $300.30 million. The stock has a 50-day moving average price of $2.99 and a 200-day moving average price of $2.96. Antares Pharma has a 52-week low of $1.41 and a 52-week high of $4.09.
Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01. The firm had revenue of $13.42 million for the quarter, compared to the consensus estimate of $12.99 million. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. Analysts forecast that Antares Pharma will post ($0.10) earnings per share for the current year.
WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2017/10/28/valuengine-lowers-antares-pharma-inc-atrs-to-sell.html.
In other Antares Pharma news, Director Thomas J. Garrity sold 30,000 shares of the business’s stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total transaction of $105,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Leonard S. Jacob sold 230,000 shares of the business’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $4.05, for a total transaction of $931,500.00. The disclosure for this sale can be found here. Insiders own 11.60% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. Alliancebernstein L.P. purchased a new position in Antares Pharma during the 2nd quarter worth $119,000. Legal & General Group Plc purchased a new position in Antares Pharma during the 2nd quarter worth $120,000. MML Investors Services LLC boosted its holdings in Antares Pharma by 228.2% during the 2nd quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock worth $139,000 after acquiring an additional 30,000 shares during the last quarter. Credit Suisse AG purchased a new position in Antares Pharma during the 1st quarter worth $146,000. Finally, Arrowstreet Capital Limited Partnership purchased a new position in Antares Pharma during the 2nd quarter worth $174,000. 36.76% of the stock is currently owned by hedge funds and other institutional investors.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.